Learn / Public Health / Planning, monitoring and evaluating programmes
Economic evaluation and priority setting
12 minute read · 6-question quiz
What you will learn
Compare cost-effectiveness, cost-utility and cost-benefit analysis
Calculate a cost per outcome and an incremental cost-effectiveness ratio
Discuss equity and affordability alongside cost-effectiveness
Resources are limited, so choices must be made. Economic evaluation compares the costs and consequences of alternative actions to find which gives the best value.
Main types
- Cost-minimisation: outcomes are equal; choose the cheaper option.
- Cost-effectiveness analysis (CEA): compares cost per unit of a natural outcome, such as cost per life saved or per case averted.
- Cost-utility analysis (CUA): compares cost per quality-adjusted life year (QALY) or disability-adjusted life year (DALY) averted, which allows comparison across diseases.
- Cost-benefit analysis (CBA): values costs and benefits in money terms and reports net benefit or benefit-cost ratio.
Incremental cost-effectiveness ratio
When a new option costs more and works better, the key number is the ICER: the extra cost per extra unit of outcome.
Beyond cost-effectiveness
Cost-effectiveness is one input. Priority-setting must also consider:
- Equity: do poor or remote groups gain most?
- Severity of illness and financial risk protection.
- Budget impact and affordability.
- Feasibility and workforce.
- Ethics and values, including a fair process that people can see and challenge.
Health technology assessment (HTA) brings these together to advise on which services and products a health system should cover. Many countries, including those building UHC benefit packages, use explicit criteria.
Summary
Economic evaluation compares costs and consequences to help choose between options.
CEA uses natural units, CUA uses QALYs or DALYs, and CBA values everything in money.
The ICER is extra cost divided by extra effect and is compared with a threshold.
Equity, affordability, feasibility and fair process matter alongside cost-effectiveness.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.